相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
Jan Hillert et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Anders Svenningsson et al.
LANCET NEUROLOGY (2022)
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
Nasim Nehzat et al.
NEUROLOGY RESEARCH INTERNATIONAL (2021)
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study
Sebastiano Bucello et al.
JOURNAL OF NEUROLOGY (2021)
Exit strategies for needle fatigue in multiple sclerosis: a propensity score-matched comparison study
Luca Prosperini et al.
JOURNAL OF NEUROLOGY (2020)
Optimal approximate conversions of odds ratios and hazard ratios to risk ratios
Tyler J. VanderWeele
BIOMETRICS (2020)
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
Robert T. Naismith et al.
CNS DRUGS (2020)
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
Michael Guger et al.
JOURNAL OF NEUROLOGY (2020)
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
Emanuele D'Amico et al.
JOURNAL OF NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017
Patrick Vermersch et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Challenges in meta-analyses with observational studies
Silvia Metelli et al.
EVIDENCE-BASED MENTAL HEALTH (2020)
Comparative effectiveness of teriflunomide and dimethyl fumarate A nationwide cohort study
Mathias Due Buron et al.
NEUROLOGY (2019)
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study
Robert Zivadinov et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Dalia Rotstein et al.
NATURE REVIEWS NEUROLOGY (2019)
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
David-Axel Laplaud et al.
NEUROLOGY (2019)
Head-to-head drug comparisons in multiple sclerosis Urgent action needed
Carmen Tur et al.
NEUROLOGY (2019)
Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study
S. Conde et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Tomas Kalincik et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US
Daniel Ontaneda et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2018)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Tomas Kalincik et al.
BRAIN (2017)
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
Aaron Boster et al.
NEUROLOGY AND THERAPY (2017)
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials
Andrew Anglemyer et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Review of methodological issues of clinical trials in multiple sclerosis
Xavier Montalban
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
D. Cadavid et al.
NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
